Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) reported its first quarter 2026 financial results following the divestiture of its Biosecurity business. Revenue for Q1 2026 was $19 million, down 49% from $38 million in the prior year period, or down 37% to $19 million from $31 million excluding non-cash deferred revenue. The company posted a GAAP net loss from continuing operations of $(76) million and Adjusted EBITDA of $(42) million. Cash, cash equivalents, and marketable securities totaled $373 million as of March 31, 2026. Ginkgo reaffirmed its expected total cash burn of $(150)-$(125) million for full year 2026.